Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant rituximab for young patients with Graves' hyperthyroidism
2016-000209-35Phase 2Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Graves' disease, sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Remission at 24 months. Started Apr 2016; status: completed.
02
Drugs
rituximab
03
Conditions
Graves' disease
Beyond the preview
Go deeper on 2016-000209-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000209-35.